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Summary. Background: Acetylsalicylic acid (ASA) is recommended before, during and after carotid endarterectomy (CEA). The efficacy of ASA is influenced by numerous biological and genotypic factors. Objectives: To determine the biological efficacy of ASA by using the Multiplate â method, and to explore the biological parameters and genomic factors influencing this efficacy. Methods: This descriptive cross-sectional study included all patients scheduled for CEA between January 2012 and April 2013. Multiplate â tests were performed at day 0 and day 30. A set of 66 single-nucleotide polymorphisms (SNPs) from 38 genes or DNA regions were selected and studied along with phenotypic parameters by the use of hierarchical clustering (HC) for multidimensional data management. Results: Fifty-five patients receiving ASA were analyzed. Of the patients, 95% were found to be sensitive to ASA, with values under the threshold of normality (400 AU min -1 ). However, there were notable differences in residual aggregation among subjects over a wide range. HC revealed four subclusters comprising three categories of parameters: (i) routine and functional parameters -in ASA-treated patients, the ASPItest was highly linked to the ADPtest, to platelet count, and, to a lesser extent, to fibrinogen and hematocrit; (ii) polymorphisms in genes involved in ASA absorption and in the arachidonic acid pathway (ABCB1 and COX-1); and (iii) polymorphisms in genes modulating basal platelet function, i.e. TBXA2R, ADRA2A, PEAR1, ITGA2 and ITGB1. Conclusion: Most patients treated with ASA before CEA were sensitive to it, according to Multiplate
Introduction
As indicated by the latest Cochrane review [1] , antiplatelet drugs reduce the risk of stroke in patients undergoing carotid endarterectomy (CEA). The European Society of Vascular Surgery guidelines recommend that acetylsalicylic acid (ASA) at a daily dose of 75-325 mg along with statins should be given before, during and after CEA [2] . Despite such protection, some patients suffer an ischemic stroke in the perioperative period. Various factors may be involved (hemodynamic changes, surgical techniques, etc.), one hypothesis being that, despite antiplatelet therapy, the vessels are not well protected from platelet clumping during carotid cross-clamping. A previous study reported the use of aggregometry and flow cytometry to assess the effect of ASA and clopidogrel on light transmission platelet aggregation in patients undergoing CEA [3] . It suggested a link between the platelet response to clopidogrel (but not to ASA) and clinical outcome, as assessed by intraoperative transcranial Doppler monitoring. Light transmission aggregometry (LTA) and flow cytometry are not routinely available. Instead, the Multiplate â method works by impedance aggregometry (IA)
on whole blood, and determines, < 10 min, whether antiplatelet drugs are active or not. It is easy to use in current practice [4] . We have already used it in stroke patients, and have shown that IA-defined high on-treatment platelet reactivity is associated with inflammation and stroke severity [5] . To our knowledge, no other study of Multiplate â results in patients benefiting from CEA has been carried out. In the only study published in similar patients with Multiplate â assessment, the procedure was carotid artery stenting rather than CEA [6] .
Monitoring the efficacy of antiplatelet therapy before and during surgery may be useful for individually tailoring the patient's management, but unraveling the factors involved in ASA low or high on-treatment platelet reactivity, or, more accurately, high or low on-treatment reactivity, is another issue. At a time when personalized medicine is emerging, better knowledge of the genetic background influencing platelet functions and response to therapy may help clinicians to obtain information upstream even before a functional test is implemented. Other, more common, parameters, such as routine blood cell count, mean platelet volume, and fibrinogen measurements, are also meaningful in many clinical situations, and are potentially related to IA reactivity and to the vascular risk.
We examined these parameters and the main single-nucleotide polymorphisms (SNPs) described in the literature regarding platelet function and response to antiplatelet drugs.
The aims of this study were thus to determine the biological efficacy of ASA by screening platelet aggregation with the Multiplate â method at the moment of crossclamping during CEA, and to explore the factors influencing this efficacy.
Materials and methods
This single-center study was carried out in a cohort of patients undergoing CEA from January 2012 to April 2013 and prospectively followed for 6 months after CEA. The study was approved by our institutional committee (Comit e de Protection des Personnes Sud-Ouest et OutreMer III, Bordeaux, France; chairperson R. I. Galperine; no. DC 2011/42). Written informed consent was obtained from all patients. The primary endpoint was the biological activity of antiplatelet therapy measured by the use of Multiplate â during carotid artery cross-clamping. Secondary endpoints were factors influencing its biological activity. Outcomes included perioperative complications, neurovascular morbidity, and mortality at 1 month and 6 months.
The indication for surgical treatment was symptomatic carotid stenosis of ≥ 50% or asymptomatic carotid stenosis of ≥ 70% in men and ≥ 80% in women with an estimated life-expectancy of > 5 years. All symptomatic patients had presented with neurological symptoms in the carotid territory (stroke or transient ischemic attack [TIA]) within 6 months preceding the operation. Cardiac investigations were performed systematically to rule out an embolic cause. Carotid stenosis was quantified by duplex ultrasound with the North American Symptomatic Carotid Endarterectomy Trial method [7] , complemented by a computed tomography scan or magnetic resonance imaging. Biological tests were carried out at day 0 and day 30. The exclusion criteria were as follows: age < 18 years, a patient's refusal to be included, thrombocytopenia of < 100 G L À1 (because Multiplate â analysis is not valid in the event of thrombocytopenia), blood analysis unavailable at the time of surgery, and emergent surgery for unstable atherosclerosis. Patients who received a single dose of clopidogrel (75 mg) on the day before surgery, depending on the surgeon's preference, were not included in the analysis. All patients scheduled for carotid surgery received 160 mg of ASA chronically. During the preoperative work-up, antiplatelet therapy was initiated or modified as follows: patients already receiving ASA had no change in treatment; those with no antiplatelet treatment received 160 mg of ASA for at least 1 week before surgery; and those receiving a different antiplatelet drug (mainly clopidogrel) had their treatment switched to ASA 160 mg 5 days before surgery after checking that they had no contraindication.
All surgical procedures were carried out under general anesthesia. Patients were discharged between postoperative day 3 and postoperative day 5, according to their degree of recovery. One month and 6 months after the intervention, all patients underwent a duplex examination and were examined by their surgeon, who filled in the standardized form.
Blood collection was standardized. BD (Franklin Lakes, NJ, USA) Vacutainer glass citrate tubes (3.2%) were sampled via a non-heparinized arterial catheter after induction of general anesthesia and before the beginning of surgery. A second withdrawal (venous) was carried out 30 days after surgery. Tubes were processed in the 2 h following withdrawal for Multiplate â analysis (Roche Diagnostics, Rotkreuz, Switzerland), thereby complying with the manufacturer's instructions, which specify a delay of < 3 h. Since the initial description of the principle [8] , the method has been described by many authors (e.g. Velik-Salchner et al. [9] ). Prior to the study, we defined the normality threshold values from the 5th percentile of a previous series of untreated controls (n = 145). For a patient receiving ASA, treatment was considered efficient if residual aggregation was < 400 AU min À1 as determined with the ASPItest (the threshold value of the ADPtest is 390 AU min À1 for patients receiving clopidogrel). We expected to include both ASA-treated and clopidogrel-treated patients in the study. Finally, the clopidogrel group represented only one-third of all of the patients, and clopidogrel was, for most of the time, associated with ASA, which complicated the analysis. This explains why the present study focused on ASA-treated patients, even though both the ASA pathway and the clopidogrel pathway were explored. Multiplate â analysis was performed at each sample time, along with blood cell count and fibrinogen measurements. We also performed Multiplate â analysis on day 30 to evaluate the consistency of ASA efficacy over a treatment period of no less than 5 weeks. SNP selection was based mostly on data published up to 2014. A set of 68 SNPs from 38 genes or DNA regions was selected for further study. Genotyping of the different SNPs expected to be closely related with platelet functions and antiplatelet drug metabolism was performed with the Sequenom (San Diego, CA, USA) technique. DNA was isolated from leukocytes in citrated tubes with the WIZARD Promega (Fitchburg, WI, USA) method. Sixtyfour SNPs from 36 genes were studied with the Sequenom technique. Sequenom MassARRAY iPLEX SNP typing was performed at the Genome Transcriptome Facility in Bordeaux and according to the manufacturer's instructions. Primers used for PCR and single-base extension were designed with ASSAY DESIGNER software (Sequenom). Genotype data were automatically called and visualized for clustering with TYPER 4.0 (Sequenom). Apart from two SNPs that were unassigned (CES1 rs71647871; PTGS1 rs5789), the other SNPs had genotyping call rates of 100%. Two SNPs had been previously genotyped with the TaqMan method (CYP2C1 rs4244285; PON1 rs662) by use of the primers described by Sibbing [10] , and both methods were in perfect agreement.
Two further TaqMan assays were carried out by using commercial kits from Life Technologies (Carlsbad, CA, USA): Pear1 rs120341331 and TBXA2R rs1131882 (TaqMan Drug Metabolism Genotyping Assays). The complete list of SNPs included in the study, and the primers and probes used, are given in Table S1 ).
Genotypic tests (general genetic model) were carried out with a v 2 test of independence (comparison with the Sequenom control population). Exact Pearson's v 2 tests were performed, and P-values were considered to be significant when they were lower than the P-value threshold defined after Bonferroni correction for multiple testing to control for type I errors (P-value of 0.001).
We used HIERARCHICAL CLUSTERING EXPLORER software (HCE3.5, available at http://www.cs.umd.edu/hcil/hce/) [11] for multidimensional data management. Data were normalized. SNP dissimilarity was specified by the use of pairwise centered Pearson's correlation coefficient with the average-linkage algorithm (unweighted pair group method with arithmetic mean) with the Pearson correlation coefficient for similarity measure. Dendrograms were plotted to illustrate the distances between the genotypes. Briefly, hierarchical clustering (HC) analysis is an iterative classification (or clustering) method whose results are usually represented as dendrograms. A dendrogram is a binary tree in which each data item corresponds to a terminal node of the binary tree, and in which the distance from the root to a subtree indicates the similarity of the subtree: the shorter the height of the subtree, the more similar the parameters. Statistical analyses were performed with XLSTAT (Addinsoft, Paris, France).
Results
From January 2012 to April 2013, 92 patients underwent CEA. Eleven patients were excluded from the study, nine for technical reasons (failure in blood sample collection or analysis) and two because of thrombocytopenia. A total of 81 patients were eligible for analysis. Fifty-five patients were operated on under ASA alone; 26 were treated with an additional dose of clopidogrel 12 h before surgery. We chose to concentrate our analysis on the 55 patients who received only ASA, for the sake of homogeneity. Table 1 summarizes the demographic characteristics, treatments and carotid lesions of these 55 patients. The 26 patients who were also treated with clopidogrel had symptomatic carotid stenosis more often (76.9% versus 50.9%, P = 0.03) and took angiotensin-converting showed a lack of protection by antiplatelet therapy.
Genotypic tests showed no significant difference in allelic distribution between the patients and Sequenom controls. Moreover, the minimum allelic frequency (MAF) observed in our patients is well correlated with the MAF described in the world population.
When the clustering threshold was set at a minimum similarity of > 0.705, HC of the different factors included in the study showed an impressive merging of the parameters expected to influence or to be linked to ASA activity as assessed with the Multiplate â ASPItest, as shown in Figs 2 and 3. Our primary intention was to investigate the factors potentially influencing platelet aggregation in ASA-treated and clopidogrel-treated patients. Therefore, besides the routine parameters such as platelet count, fibrinogen, hematocrit, and the molecular variants affecting the basal machinery of platelet functions, we also investigated a series of genes likely to modulate the response to ASA or clopidogrel. After restriction of our analysis to ASA-treated patients, all of the parameters remained included in our design, and the ASPItest results were, in a cluster of parameters, highly related to basal platelet function, to ASA metabolism, and to the action of thromboxane. As clopidogrel-treated patients were excluded from the study, a greater distance between the parameters linked to the action of clopidogrel (e.g. CYP2C19, CYP1A2, and CYP3A4) and the functional tests (ASPItest and ADPtest) was expected and confirmed. Figure 3 shows the main clusters of interest for the functional tests (ADPtest and ASPItest). Increasing the minimal similarity requirement to 0.722 revealed four subclusters comprising three categories of parameters: 1. Routine and functional parameters. In ASA-treated patients, the ASPItest was highly linked to the ADPtest (r = 0.495), to platelet count (r = 0.476), and, to a lesser extent, to fibrinogen and hematocrit; 2. Polymorphisms in genes involved in ASA absorption and in the arachidonic acid pathways, i.e. ABCB1 and COX-1; 3. Polymorphisms in genes modulating platelet function, i.e. TBXA2R, ADRA2A, PEAR1, ITGA2 and ITGB1.
Discussion
This Multiplate â analysis in patients undergoing CEA revealed that, at the time of carotid cross-clamping, 5.4% of patients were not protected by ASA. It also revealed the tremendous difference in platelet aggregation among patients, even in the main group of patients achieving the < 400 AU min À1 threshold of efficiency.
In recent years, neurologists from our institution have been using Multiplate â results to determine the biological efficacy of antiplatelet treatment in patients suffering from stroke, and have already demonstrated the high frequency of high on-treatment platelet reactivity (18.4%) and its association with inflammation and stroke severity [5] . Thanks to its simplicity and short processing time, we decided to use it to screen our CEA patients. Its diagnostic performances are comparable to those of LTA, which is the gold standard, but it also avoids the need to prepare platelet-rich plasma [9] . Payne et al., who first studied platelet aggregation in patients scheduled for carotid surgery, used whole blood flow cytometry [12] , but this test requires extensive laboratory preparation, and was not suitable for our study. The coefficients of variation for repeated Multiplate â measurements were 11% for the ADPtest and 10% for the ASPItest, which is acceptable for a biological test [13] . We determined cut-off values from a population of 145 volunteers. Peerschke demonstrated the importance of establishing locally relevant reference ranges [14] , and our series of 145 normal volunteers illustrates the most appropriate way to define these cut-offs. Moreover, our locally defined threshold for defining sensitivity to ASA is in line with the values described by Al-Azzam et al. [15] and chosen by the provider as the cut-off value (in hirudin blood samples) in the ASPItest Package Insert (06673821001V2).
We results varied as the delay between blood sampling and analysis increased [16] . For this reason, all of our samples were analyzed in the first 2 h after sampling to reduce this variability. During the study, Multiplate â was used just before surgery and the results were analyzed a posteriori, so we did not adapt the antiplatelet regimen during the procedure. However, Multiplate â could be used in preoperative consultations when CEA surgery is being planned to avoid the ineffectiveness of antiplatelet treatment during carotid cross-clamping, which was still the case in 5.4% of our patients. As monitoring of treatment effect by thromboxane measurement was not available in the patients, it was not possible to know whether the inefficacy of the antiplatelet therapy was attributable to its biological inefficacy or to patients' non-compliance with treatment. We searched for factors influencing the quantitative ASPItest results rather than simply binary values (above or below the threshold of 400 AU min À1 ). In any event, the wide interindividual variation in residual platelet function after stimulation with arachidonic acid remains to be explained. Some routine laboratory parameters are already known to interfere with the Multiplate â response: ADPtest [17] , platelet count, fibrinogen, and hematocrit. First, the ADPtest had the highest correlation coefficient with the ASPItest among the parameters studied. The R-value obtained in the 93 measurements of day 0 and day 30 samples (R = 0.495) is higher than that obtained in our daily Main cluster of the study routine in more diverse therapeutic conditions, in which the R-value is only 0.420 (ADPtest and ASPItest carried out on the same samples, n = 1000). This probably means that, besides the inhibitory action of ASA, there are some interindividual differences in platelet excitability, rather than a direct effect of ASA on ADP-induced aggregation, which has been reported not to occur [18] . Platelet count was also found in the main cluster around the ASPItest, and Femia nicely demonstrated in vitro its relationship with the Multiplate â results after stimulation with thrombin receptor-activating protein, collagen, or ADP [19] . However, in patients receiving antiplatelet drugs, the effect of platelet count is blunted by the predominant effect of the treatments, and this relationship is weaker, as found in 400 successive ASAtreated patients analyzed in our laboratory (R = 0.364). A strong epidemiological association between plasma fibrinogen concentration and platelet aggregability was reported long ago by Meade [20] , and hematocrit has been shown to influence significantly the VerifyNow P2Y12 assay but not the Multiplate â assay [21] . Both were modestly linked to the ASPItest in the main cluster. Among the 66 SNPs included in our study, only some of them, belonging to eight genes, clustered near the ASPItest results. All but one has already been reported to be linked to ASA efficiency. The first group concerns ASA absorption (ABCB1) and the arachidonic acid pathway (COX-1). It has been shown experimentally that ASA efflux occurs through the MDR1 transporter (a more common name for ABCB1) [22] , and ABCB1 C3435T (rs1045642) has recently been shown to be related to ASA resistance in Chinese patients with ischemic stroke [23, 24] . Genetic variability in COX-1 has already been shown to modulate both arachidonic acidinduced platelet aggregation and thromboxane generation [25] . A variant of COX-1, Q41Q (rs3842788), is also a specific genetic marker of ASA resistance in Chinese chronic stable angina patients, along with rs5911 from the ITGB2 gene [26] .
The second group of ASPItest-linked genotypes covers a series of genes involved in individual platelet reactivity: ITGA2, ITGB1, TXA2R, ADRA2A and PEAR1. Polymorphisms affecting genes coding for integrins a 2 and b 1 , i.e. ITGA2 and ITGB1, have already been implicated in ASA insensitivity [27] . ITGA2 mediates platelet adhesion to collagen, and ITGA2 rs1126643 (redundant with rs1062535) is also related to stroke [28] and myocardial infarction [29] in younger patients, and to increased risk of cardiovascular mortality in high-risk women (smoking, and with compromised endothelium) [30] . The receptor for thromboxane A 2 (TXA2) plays a major role in platelet activation, and the rs1131882 variant of TXA2R has already been shown to influence platelet reactivity significantly, as assessed with PFA-100, in diabetic patients receiving ASA, along with the variant rs553668 in ADRA2A, which codes for the a 2 -adrenergic receptor of epinephrine [31] . In diabetic patients, TXA2R rs1131882 has also recently been confirmed, by a genome-wide genotyping approach, to contribute to platelet reactivity and to impact on the long-term survival of diabetic patients treated with ASA [32] . The platelet endothelial aggregation receptor 1 gene (PEAR1) is highly expressed in platelets and endothelial cells, and the protein that it encodes signals secondarily to a IIb b 3 -mediated platelet-platelet contacts [33] . PEAR1 rs12041331 has been shown to influence platelet aggregation in ASA-treated patients with coronary artery disease [34] . POR encodes NADPH:cytochrome P450 oxidoreductase (reviewed in [35] ), and POR*28 31696C>T (rs1057868) was included in the design because of its potential involvement in the cytochrome P450-catalyzed metabolism of certain drugs, such as clopidogrel. Its presence in the same cluster as those genes linked to ASA-related platelet functional effects and metabolism is probably incidental.
Minimum similarity = 0.722 Main cluster of interest for the study This study has several potential drawbacks. The main limitations are its observational design and the small number of patients screened, so the findings now need to be confirmed in a larger cohort and extended to clopidogrel-treated patients. Furthermore, new variants associated with platelet function are described year after year. Selecting SNPs for a genotyping study is always a source of frustration as new markers become available, such as the recently described RGS7 rs12744536 and ANKS1B rs398098426 in ischemic stroke patients with coexisting large-vessel atherosclerosis [36] .
Multiplate â was not compared with another test, and there is an active controversy about the most relevant method to rapidly screen platelet functions [37] [38] [39] [40] [41] . Currently, there is no real gold standard test for measuring on-treatment platelet reactivity. The closest to its definition is LTA, which is the oldest method for evaluating platelet function. However, it is very time-consuming, and requires skilled technicians and large sample volume, so it is not widely used either in clinical practice or in most scientific publications [42] . Multiplate â is a far more userfriendly device, especially in clinical practice. Several studies have shown that whole blood aggregometry is more sensitive to the effect of antiplatelet drugs than LTA, and could detect ASA effects for a longer period of time in healthy controls [43, 44] . Pedersen et al. showed that the repeatability of whole blood aggregometry was good in healthy individuals at baseline, with a coefficient of variance (CV) value of 8%, whereas it was 46% during ASA treatment in both healthy individuals and patients [45] . More recently, a study comparing five platelet function tests also showed that intra-assay and interassay CVs of the Multiplate â device increased with the intake of ASA treatment, from 5.2% to 16.3%, and from 9.7% to 24.7%, respectively [46] . For a similar absolute variation, CVs are more affected when the denominator is low (when patients are ASA-treated and Multiplate â values are low); even a 25% CV on low aggregation data will not greatly affect the large difference observed between patients and controls ( Fig. 1) . Initially, we aimed to include all patients scheduled for CEA in our institution. Mixing multiple therapeutic regimens in unequal patient subgroups proved to be too confusing, so we focused our attention on the ASA-treated patients only. Finally, as noted above, we did not explore patients' compliance with treatment.
In conclusion, most patients treated with ASA before CEA were sensitive to it according to Multiplate â ASPItest results. However, we observed a large difference in interindividual platelet sensitivity to this drug. Most of the factors found to be linked to the functional state of platelets as assessed by Multiplate â in these patients have already been described in the literature, although separately. Although these findings do not call for an immediate change in patient management, they shed light on the multiple mechanisms underpinning the large interindividual variation in the functional efficiency of ASA, and should ultimately lead to the implementation of more personalized patient care.
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